Teva Pharmaceutical Industries Ltd. and Samsung Bioepis Co., Ltd. announced that they entered into a licensing ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...

Samsung Bioepis and Teva have entered into a license, development and commercialization agreement for Epysqli (eculizumab-aagh), which is Samsung Bioepis’s biosimilar to Soliris. Samsung Bioepis ...

The FDA approved EPYSQLI in July 2024. Prior to its approval, Alexion had sought a preliminary injunction, but the Court denied the motion in May 2024, finding that Alexion had failed to ...

Last year was a big year for Fairbanks Museum, highlighted by major moments in the museum’s 136-year history, but in 2025, the museum will focus on the smaller things, both literally and ...

Teva also recently announced a collaboration with Samsung Bioepis for the commercialization of Epysqli (eculizumab-aagh), a biosimilar to Soliris (eculizumab) for the treatment of rare diseases, ...

Baca Juga Kyung-Ah Kim Named as President and Chief Executive Officer of Samsung Bioepis EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal ...

Samsung Bioepis announced on the 12th that it has signed a commercialization partnership agreement with Teva Pharmaceutical Industries to enter the U.S. market with the rare disease treatment ...

Sana’a, Jan 12 (EFE).- Several people died and more than 70 suffered injuries after an explosion of a liquefied gas depot in a central area of Yemen, medical sources said on Sunday. The ...

EPYSQLI is a complement inhibitor indicated for the treatment of rare disease patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to ...

The 26-year-old was originally slated to fight the Japanese boxing megastar on Christmas Eve but suffered a cut above his left eye. UFC 311: MAKHACHEV VS TSARUKYAN 2 | SUN 20 JAN | Order Now with ...